Exclusive to Acupath Labs (NY), the URO17™ ICC stain has demonstrated greater than 95% Sensitivity and Specificity for the detection of both low and high grade bladder cancer in recent published studies. Used as an adjunct to cytology on the same voided urine specimen, URO17™ is highly expressed in urothelial carcinoma and has the potential to revolutionize how bladder cancer is detected, managed, and treated. Acupath offers the assay on both a Global and TC only basis as part of its Advanced Bladder Cancer Detection Panel, which also includes urine cytology and FISH.
